Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and small molecule therapies for ophthalmic disorders, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.
CEO George Magrath, MD, and Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, will deliver a corporate update presentation, available on demand starting September 8, 2025 at 7:00 a.m. ET. The company also noted that replays from recent investor events, including a Nasdaq Spotlight interview and other presentations, are available on their website's Investors section.
Opus Genetics (Nasdaq: IRD), società biofarmaceutica in fase clinica focalizzata su terapie geniche per malattie retiniche ereditarie e su terapie a piccola molecola per disturbi oftalmici, parteciperà alla H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025.
Il CEO George Magrath, MD, e il Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, presenteranno un aggiornamento aziendale disponibile on demand a partire dall'8 settembre 2025 alle 7:00 ET. La società ha inoltre comunicato che le registrazioni di recenti eventi per investitori, inclusa un'intervista Nasdaq Spotlight e altre presentazioni, sono disponibili nella sezione Investors del loro sito web.
Opus Genetics (Nasdaq: IRD), una compañía biofarmacéutica en fase clínica centrada en terapias génicas para enfermedades hereditarias de la retina y en terapias con pequeñas moléculas para trastornos oftálmicos, participará en la H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025.
El CEO George Magrath, MD, y el Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, ofrecerán una presentación de actualización corporativa, disponible bajo demanda a partir del 8 de septiembre de 2025 a las 7:00 a.m. ET. La compañía también indicó que las repeticiones de eventos recientes para inversores, incluida una entrevista en Nasdaq Spotlight y otras presentaciones, están disponibles en la sección Investors de su sitio web.
Opus Genetics (Nasdaq: IRD)는 유전성 망막 질환을 위한 유전자 치료제와 안과 질환을 위한 소분자 치료제에 주력하는 임상 단계 생명공학 기업으로, H.C. Wainwright 27th Annual Global Investment Conference에 2025년 9월 8일부터 10일까지 참가합니다.
CEO George Magrath, MD와 최고과학개발책임자 Ash Jayagopal, Ph.D., MBA가 기업 업데이트 발표를 진행하며, 해당 발표는 2025년 9월 8일 오전 7:00(동부시간)부터 온디맨드로 시청할 수 있습니다. 또한 최근 투자자 행사(나스닥 스포트라이트 인터뷰 및 기타 발표 포함)의 재방송도 웹사이트의 Investors 섹션에서 이용 가능하다고 밝혔습니다.
Opus Genetics (Nasdaq: IRD), une société biopharmaceutique en phase clinique spécialisée dans les thérapies géniques pour les maladies rétiniennes héréditaires et les petites molécules pour les troubles ophtalmiques, participera à la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025.
Le CEO George Magrath, MD, et le Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, présenteront une mise à jour corporate, disponible à la demande à partir du 8 septembre 2025 à 7h00 ET. La société a également précisé que les rediffusions des récents événements investisseurs, y compris une interview Nasdaq Spotlight et d'autres présentations, sont disponibles dans la rubrique Investors de leur site web.
Opus Genetics (Nasdaq: IRD), ein Biopharmaunternehmen in klinischer Phase, das sich auf Gentherapien für erbliche Netzhauterkrankungen und auf niedermolekulare Therapeutika für ophthalmische Störungen spezialisiert hat, wird an der H.C. Wainwright 27th Annual Global Investment Conference vom 8. bis 10. September 2025 teilnehmen.
CEO George Magrath, MD, und Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, werden ein Unternehmensupdate präsentieren, das ab dem 8. September 2025 um 7:00 Uhr ET auf Abruf verfügbar ist. Das Unternehmen wies zudem darauf hin, dass Wiederholungen kürzlicher Investorenveranstaltungen, darunter ein Nasdaq-Spotlight-Interview und weitere Präsentationen, im Investor-Bereich ihrer Website abrufbar sind.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jayagopal, Ph.D., MBA, Chief Scientific and Development Officer, will deliver a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. The presentation will be available on demand on Monday, September 8, 2025 at 7:00 a.m. ET.
In addition, replays from other recent investor events are available on the Opus Genetics’ website, including:
- Nasdaq Spotlight interview
- Chardan Virtual Ophthalmology Summit Series on Rare Ophthalmic Diseases Fireside Chat
- Jones Trading Virtual Presbyopia Expert Panel
Links to these webcasts may be accessed on the Opus Genetics website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
When is Opus Genetics (IRD) presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for Opus Genetics at the H.C. Wainwright Conference?
What type of treatments is Opus Genetics (IRD) developing?
Where can investors access Opus Genetics' conference presentation and other recent webcasts?
